Abbott Laboratories
ABT
Below: live stock price for Abbott Laboratories (ABT), a 1-year chart, 8 indicators (RSI, MACD, Bollinger, MA, EMA, Stochastic, ATR, Volume), and a compare mode. Add to your portfolio, star to your watchlist, or set a price alert in one place.
Abbott Laboratories (ABT) is a Healthcare company based in United States. Operating in Medical Devices, it employs about 122,000 people. Over the past year ABT traded between 81.97 and 137.49 USD. Trailing P/E sits near 28.2 on a market cap of about 175.37B USD. It currently yields 2.50% in dividends.
- Prev close
- $98.83
- Volume (24h)
- $1.72B
- Market cap
- $175.37B
- Currency
- USD
Score
49/ 100 · Mixed
- Value52
- Quality74
- Momentum21
- Growth24
- Risk79
- Dividend42
- Liquidity—
Composite of public market data. Informational only — not investment advice.
Trend projection
Where the recent trend points if it continues.
- +5 bars
- 101.1581 +0.47%
- +20 bars
- 101.8216 +1.13%
- +60 bars
- 102.0795 +1.39%
- +120 bars
- 102.0889 +1.40%
Linear-regression continuation — not a prediction, not investment advice. ±1σ ≈ 68% range · ±2σ ≈ 95% range: ±0.0352 USD.
Interpretation
Composite signals look mixed. Strength: risk profile with weakness: momentum. Price sits near the upper third of the recent range, trend is sloping upward.
Descriptive observation — not investment advice.
Score breakdown
Raw values behind each pillar so you can see what the composite is reading.
- Value52/100
Value looks mixed — driven by P/E (28.2).
P/E:28.2P/B:3.37PEG:1.5 - Quality74/100
Quality looks solid — driven by Gross margin (56.77%).
Profit margin:11.65%Gross margin:56.77% - Momentum21/100
Momentum looks fragile — driven by 52w change (-19.08%).
52w change:-19.08% - Growth24/100
Growth looks fragile — driven by Earnings growth (-47.50%).
Revenue growth:13.00%Earnings growth:-47.50% - Risk79/100
Risk looks strong — driven by Debt / equity (64.77).
Beta:0.61Debt / equity:64.77Short interest:1.50% - Dividend42/100
Dividend looks weak — driven by Payout ratio (67.23%).
Dividend yield:2.50%Payout ratio:67.23%
Derived from public market data — informational, not investment advice.
Reference levels
Fibonacci retracements and extensions across the recent range.
Reference only — not investment advice.
These coordinates describe past-trade clustering, not where to buy or sell. Do your own research before any trade.
- ResistanceFib +161.8% extension134.7489 USD+33.84% from current
- ResistanceFib +100% extension122.29 USD+21.46% from current
- ResistanceFib +61.8% extension114.5889 USD+13.81% from current
- ResistanceFib +27.2% extension107.6135 USD+6.89% from current
- Current100.68 USD
- SupportFib 23.6% retracement97.3722 USD-3.29% from current
- SupportFib 38.2% retracement94.4289 USD-6.21% from current
- SupportFib 50% midpoint92.05 USD-8.57% from current
- SupportFib 61.8% retracement89.6711 USD-10.93% from current
- SupportFib 78.6% retracement86.2842 USD-14.30% from current
- SupportFib −27.2% extension76.4865 USD-24.03% from current
- SupportFib −61.8% extension69.5111 USD-30.96% from current
- SupportFib −100% extension61.81 USD-38.61% from current
Financials
- 52w high
- $137.49
- 52w low
- $81.97
- 52w change
- -19.08%
- Day high
- $102.13
- Day low
- $99.47
- P/E (TTM)
- 28.2
- Forward P/E
- 16.6
- PEG
- 1.5
- Price / Book
- 3.37
- Beta (5Y)
- 0.61
- Enterprise value
- 202.85B
- EV / Revenue
- 4.35
- EV / EBITDA
- 17.09
- EPS (TTM)
- $3.57
- Forward EPS
- $6.07
- Dividend yield
- 2.50%
- Dividend rate
- $2.52
- Payout ratio
- 67.23%
- Revenue (TTM)
- 46.58B
- EBITDA
- 11.87B
- Total cash
- 7.3B
- Total debt
- 34.14B
- Debt / Equity
- 64.77
- Profit margin
- 11.65%
- Gross margin
- 56.77%
- Shares outstanding
- 1.74B
- Float
- 1.73B
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.
Analyst & Risk
- Beta (vs S&P 500)
- 0.61
- less volatile
- 52-week change
- -19.08%
- Short % of float
- 1.50%
- Short ratio (days)
- 1.67
- Debt / Equity
- 64.77
- very high leverage
- PEG ratio
- 1.5
- fair
- EV / Revenue
- 4.35
- EV / EBITDA
- 17.09
- Revenue growth
- 13.00%
- Earnings growth
- -47.50%
- EBITDA
- 11.87B
- Total cash
- 7.3B
- Total debt
- 34.14B
- Insider holdings
- 0.49%
- Institutional
- 82.43%
Recent rating changes
- 2026-07-17CitigroupBuy → Buymain
- 2026-07-17Piper SandlerOverweight → Overweightreit
- 2026-07-17JP MorganOverweight → Overweightmain
- 2026-07-17Wells FargoOverweight → Overweightmain
- 2026-07-17TD CowenBuy → Buyreit
- 2026-07-17Evercore ISI GroupOutperform → Outperformmain
- 2026-07-17RBC CapitalOutperform → Outperformreit
- 2026-07-17BTIGBuy → Buymain
Financial documents
- Corporate Changes & Voting Matters8-K2026-07-16
- Annual report of employee stock purchase11-K2026-06-18
- Specialized Disclosure Report filed pursuant to Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act relating to the use of conflict minerals (Rule 13p-1)SD2026-05-27
- Periodic Financial Reports10-Q2026-04-29
- Corporate Changes & Voting Matters8-K2026-04-27
- Offering RegistrationsS-82026-04-24
- Corporate Changes & Voting Matters8-K2026-04-17
- Corporate Changes & Voting Matters8-K2026-04-16
- Offering RegistrationsS-82026-03-23
- Proxy StatementsDEFA14A2026-03-13
- Corporate Changes & Voting Matters8-K2026-03-09
- Corporate Changes & Voting Matters8-K2026-02-26
Recent news
- My 2 Favorite Dividend Kings to Buy Right NowMotley Fool13h ago
- The Justice Department Is Pulling Back on Prosecuting Corporate CrimeThe Wall Street Journal1d ago
- ABT Q2 Earnings Call Flags Stronger Second-Half SetupZacks2d ago
- Abbott Laboratories Seen on Track for H2 Growth Acceleration, RBC SaysMT Newswires2d ago
- BTIG Adjusts Price Target on Abbott Laboratories to $134 From $131, Maintains Buy RatingMT Newswires2d ago
- Piper Sandler Adjusts Price Target on Abbott Laboratories to $118 From $115, Maintains Overweight RatingMT Newswires2d ago
- JPMorgan Adjusts Price Target on Abbott Laboratories to $120 From $110, Maintains Overweight RatingMT Newswires2d ago
- Evercore ISI Adjusts Price Target on Abbott Laboratories to $120 From $112, Maintains Outperform RatingMT Newswires2d ago
Related
Other assets in this category.
- 8306.TMitsubishi UFJ Financial Group, Inc.3,473 USD-4.30%
- 7203.TToyota Motor Corporation2,899.5 USD-0.33%
- 9984.TSoftBank Group Corp.5,424 USD-9.01%
- 6758.TSony Group Corporation3,470 USD+0.93%
- 6861.TKeyence Corporation70,880 USD-4.28%
- NVDANVIDIA Corporation202.81 USD-2.21%
- AAPLApple Inc.333.74 USD+0.14%
- 0700.HKTencent Holdings Limited477.8 USD+3.51%
Live discussion
Sign in to join the discussion.
- No comments yet. Be the first.